carmen-lc03: tusamitamab ravtansine versus docetaxel in pre-treated nsclc
Published 1 month ago • 107 plays • Length 3:33Download video MP4
Download video MP3
Similar videos
-
0:44
com503: the next steps in harnessing cytokines to treat cancer
-
2:33
concurrent immunotherapy in sclc
-
0:42
hpn328, a tri-specific t-cell engager, in sclc and neuroendocrine cancers
-
1:16
dr. socinski on recommendations for molecular testing in lung cancer
-
1:28
clinical trial: tarlatamab for small cell lung cancer (nct04885998)
-
55:46
'lung cancer chemoprevention: targeting early carcinogenesis', presented by dr. mark geraci
-
1:33
climb360: ctdna-based molecular screening
-
1:42
dr. feldman on the future of durvalumab and tremilimumab in nsclc
-
3:15
molecular testing in lung cancer
-
3:02
elizabeth brém, md, uci - cll and lymphoma
-
2:29
dr. spigel on checkmate 017- phase iii trial for nivolumab - sarah cannon
-
4:47
clinical trial for metastatic lung cancer
-
2:40
elcc 2010: the use of monoclonal antibodies to treat mesothelioma
-
14:55
advances in diagnosing lung cancer
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
-
4:43
carcinoembryonic antigen (cea) blood test explained | use in bowel cancer monitoring
-
2:25
what is a celmod?
-
11:40
immunotherapy of myeloma: bcma/slamf7 car t-cells & bites